Disparities in the Early Adoption of Chemoimmunotherapy for Diffuse Large B-cell Lymphoma in the United States
暂无分享,去创建一个
Amy Y. Chen | C. Flowers | E. Ward | S. Fedewa | O. Brawley | J. Lipscomb | L. Nastoupil
[1] C. Flowers,et al. Examining racial differences in diffuse large B-cell lymphoma presentation and survival , 2013, Leukemia & lymphoma.
[2] L. Tanoue. Cancer Statistics, 2011: The Impact of Eliminating Socioeconomic and Racial Disparities on Premature Cancer Deaths , 2012 .
[3] C. Flowers,et al. Patterns of Social Support Among Lymphoma Patients Considering Stem Cell Transplantation , 2011, Social work in health care.
[4] W. P. Reed,et al. Improving uniformity of care for colorectal cancers through National Quality Forum quality indicators at a Commission on Cancer-accredited community based teaching hospital. , 2011, Surgical oncology clinics of North America.
[5] J. Pinilla-Ibarz,et al. Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data. , 2011, Clinical lymphoma, myeloma & leukemia.
[6] C. Flowers,et al. Racial differences in the presentation and outcomes of diffuse large B‐cell lymphoma in the United States , 2011, Cancer.
[7] J. Vose,et al. Improving Outcomes for Patients with Diffuse Large B‐cell Lymphoma , 2010, CA: a cancer journal for clinicians.
[8] B. Coiffier,et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. , 2010, Blood.
[9] J. Byrd,et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.
[10] C. Flowers,et al. Black/White Differences in the Treatment and Outcomes of Diffuse Large B Cell Lymphoma: A Matched Cohort Analysis. , 2009 .
[11] Xianglin L. Du,et al. Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population‐based cohort of elderly patients with non‐Hodgkin lymphoma , 2008, Cancer.
[12] M R Petersen,et al. Approaches for estimating prevalence ratios , 2008, Occupational and Environmental Medicine.
[13] Amy Y. Chen,et al. Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998-2005). , 2008, Journal of the National Cancer Institute.
[14] Markus Loeffler,et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). , 2008, The Lancet. Oncology.
[15] J. Foran,et al. A Comparative Study of Diffuse Large B-Cell Lymphoma (DLBCL) between African Americans and Caucasians: Single-Center Experience at the University of Alabama at Birmingham (UAB). , 2007 .
[16] L. Gary,et al. Race and Non-Hodgkin’s Lymphoma: Adverse Impact of Race and Treatment Delays on Survival. A SEER-Medicare Population Study (1995–2003). , 2007 .
[17] C. Flowers,et al. Racial differences in the incidence and outcomes for patients with hematological malignancies. , 2007, Current problems in cancer.
[18] Wen-yu Li,et al. CHOP-Like Chemotherapy Plus Rituximab Versus CHOP-Like Chemotherapy Alone in Young Patients with Good-Prognosis Diffuse Large-B-Cell Lymphoma:A Randomised Controlled Trial by the MabThera International Trial (MInT) Group , 2007 .
[19] N. Schmitz,et al. Six vs. Eight Cycles of Bi-Weekly CHOP-14 with or without Rituximab for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Completed RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). , 2006 .
[20] Randy D Gascoyne,et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] A. López-Guillermo,et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.
[22] O. Brawley. Lung cancer and race: equal treatment yields equal outcome among equal patients, but there is no equal treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] O. Brawley,et al. Cancer-related Disparities: Weathering the Perfect Storm Through Comprehensive Cancer Control Approaches , 2005, Cancer Causes & Control.
[24] R. Gascoyne,et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] R. Groman,et al. Racial and ethnic disparities in health care: a position paper of the American College of Physicians. , 2004, Annals of internal medicine.
[26] S. Kaplan,et al. The Patient's Role in Reducing Disparities , 2004, Annals of Internal Medicine.
[27] N. Powe,et al. Diversifying the Racial and Ethnic Composition of the Physician Workforce , 2004, Annals of Internal Medicine.
[28] J. Lumpkin,et al. From Unequal Treatment to Quality Care , 2004, Annals of Internal Medicine.
[29] M. Pfreundschuh,et al. Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab -early stopping after the first interim analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Marc Shapiro,et al. Prostate cancer in black and white Americans , 2003, Cancer and Metastasis Reviews.
[31] R. Fisher,et al. Diffuse aggressive lymphoma. , 2004, Hematology. American Society of Hematology. Education Program.
[32] Ruth Etzioni,et al. Estimating Health Care Costs Related to Cancer Treatment From SEER-Medicare Data , 2002, Medical care.
[33] Colin B Begg,et al. Survival of blacks and whites after a cancer diagnosis. , 2002, JAMA.
[34] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[35] Pierre Morel,et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[36] Meland,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[37] J. Vose,et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] J. Byrd,et al. Non‐hodgkin's lymphomas , 2010, Bone Marrow Transplantation.
[39] V. Diehl,et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. , 1998, Blood.
[40] R. Fisher,et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. , 1998, The New England journal of medicine.
[41] K. Melmon,et al. Clinical investigators as critical determinants in pharmaceutical innovation , 1997, Nature Medicine.
[42] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[43] T M Grogan,et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[44] N. Krieger. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. , 1992, American journal of public health.
[45] P. Allen. ICDO — International Classification of Diseases for Oncology , 1991 .
[46] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[47] C. Coltman,et al. Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma , 1976, Cancer.